ZIOPHARM Oncology, Inc. (ZIOP)
-NasdaqCM 1.71 
0.08(4.47%) 4:00PM EDT|After Hours
:
1.74 0.03 (1.75%) 5:24PM EDT
| Prev Close: | 1.79 |
|---|
| Open: | 1.82 |
|---|
| Bid: | 1.66 x 1000 |
|---|
| Ask: | 1.81 x 1500 |
|---|
| 1y Target Est: | 2.88 |
|---|
| Beta: | 1.53 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 1.71 - 1.85 |
|---|
| 52wk Range: | 1.49 - 6.33 |
|---|
| Volume: | 1,201,021 |
|---|
| Avg Vol (3m): | 2,055,800 |
|---|
| Market Cap: | 142.06M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.05 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- ZIOPHARM Oncology to Present at the 38th Annual Deutsche Bank Health Care ConferenceGlobeNewswire(Wed 7:00AM EDT)
- Apple Hits App Milestone, U.S. Bancorp Execs Unload, and 3 More Hot Stocksat Wall St. Cheat Sheet(Thu, May 16)
- 5 Stocks Seeing Bullish Options Actionat TheStreet(Thu, May 16)
- ZIOPHARM Announces Presentation of Promising Nonclinical and Phase I Study Results of Ad-RTS-IL-12 in Advanced Melanoma at ASGCT 16th Annual MeetingGlobeNewswire(Thu, May 16)
- 5 Stocks Under $10 Set to Soarat TheStreet(Thu, May 16)
- ZIOPHARM Announces Poster Presentation at the 2013 American Society for Clinical Oncology (ASCO) Annual MeetingGlobeNewswire(Wed, May 15)
- ZIOPHARM ONCOLOGY INC FinancialsEDGAR Online Financials(Tue, May 14)
- ZIOPHARM Announces First Quarter Financial Results and Key DevelopmentsGlobeNewswire(Tue, May 7)
- ZIOPHARM ONCOLOGY INC Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Tue, May 7)
- ZIOPHARM ONCOLOGY INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Tue, May 7)
- Leaders of TheStreet's Drug Approval Contestat TheStreet(Mon, May 6)
- Threshold: My Biotech Pick Of The Yearat Seeking Alpha(Tue, Apr 23)
- 4 Biotech Stocks Under $10 Making Big Movesat TheStreet(Tue, Apr 9)
- Ziopharm rises on preclinical cancer therapy studyAP(Tue, Apr 9)
- Will Ziopharm’s Positive Tests Impress These Top Institutional Shareholders?at Wall St. Cheat Sheet(Tue, Apr 9)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 185.89 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.91 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.24 |
|---|
| Mean Recommendation*: | 3.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
ZIOPHARM Oncology, Inc., a biopharmaceutical company, focuses on the development and commercialization of new cancer therapies. Its lead candidate, Palifosfamide (ZIO-201), a DNA alkylating agent, is under Phase III clinical trial for the treatmen...
View More